Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
152.43
-2.15 (-1.39%)
Feb 21, 2025, 4:00 PM EST - Market closed
Ascendis Pharma Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Net Income | -378.08 | -481.45 | -583.19 | -383.58 | -418.96 | Upgrade
|
Depreciation & Amortization | 17.25 | 18.43 | 17.51 | 14.95 | 9.45 | Upgrade
|
Other Amortization | 0.47 | 0.48 | 0.44 | 0.45 | - | Upgrade
|
Loss (Gain) From Sale of Assets | -0.09 | 0.01 | 0.02 | - | - | Upgrade
|
Asset Writedown & Restructuring Costs | - | 7.83 | - | - | - | Upgrade
|
Loss (Gain) on Equity Investments | 20.06 | 18.4 | 17.7 | -12.04 | 9.52 | Upgrade
|
Stock-Based Compensation | 95.51 | 66.66 | 64.18 | 66.83 | 53.17 | Upgrade
|
Other Operating Activities | 45.85 | 2.07 | 0.11 | -56.53 | 76.23 | Upgrade
|
Change in Accounts Receivable | -118.61 | -32.77 | -11.53 | -6.66 | -2 | Upgrade
|
Change in Inventory | -86.68 | -78.26 | -55.27 | -75.41 | - | Upgrade
|
Change in Accounts Payable | 26.97 | 3.55 | 45.94 | 39.19 | 7.88 | Upgrade
|
Change in Unearned Revenue | -1.2 | -7.08 | 8.65 | 5.2 | -0.5 | Upgrade
|
Change in Other Net Operating Assets | 72.36 | 14.77 | -0.26 | -10.05 | -6.36 | Upgrade
|
Operating Cash Flow | -306.2 | -467.36 | -495.7 | -417.65 | -271.55 | Upgrade
|
Capital Expenditures | -1.43 | -2.44 | -14.49 | -23.7 | -19.86 | Upgrade
|
Sale of Property, Plant & Equipment | 0.95 | 0.05 | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | - | - | - | -0.53 | -1.69 | Upgrade
|
Investment in Securities | 7.35 | 288.87 | 66.69 | -86.35 | -274.7 | Upgrade
|
Other Investing Activities | - | - | 9.54 | - | 5.05 | Upgrade
|
Investing Cash Flow | 6.88 | 286.47 | 61.73 | -110.58 | -291.2 | Upgrade
|
Long-Term Debt Issued | 134.16 | 136.26 | 503.28 | - | - | Upgrade
|
Long-Term Debt Repaid | -11.37 | -10.44 | -6.36 | -6.43 | -4.77 | Upgrade
|
Net Debt Issued (Repaid) | 122.79 | 125.82 | 496.93 | -6.43 | -4.77 | Upgrade
|
Issuance of Common Stock | 340.43 | 10.29 | 5.15 | 379.42 | 607.42 | Upgrade
|
Repurchase of Common Stock | - | -1.81 | -105.31 | -21.61 | - | Upgrade
|
Other Financing Activities | -19.29 | - | - | - | - | Upgrade
|
Financing Cash Flow | 443.93 | 134.29 | 396.77 | 351.39 | 602.65 | Upgrade
|
Foreign Exchange Rate Adjustments | 22.77 | -6.01 | 35.69 | 38.59 | -53.49 | Upgrade
|
Net Cash Flow | 167.38 | -52.6 | -1.5 | -138.25 | -13.59 | Upgrade
|
Free Cash Flow | -307.62 | -469.8 | -510.19 | -441.35 | -291.41 | Upgrade
|
Free Cash Flow Margin | -84.60% | -176.14% | -996.97% | -5674.38% | -4191.11% | Upgrade
|
Free Cash Flow Per Share | -5.31 | -8.35 | -9.10 | -8.06 | -5.76 | Upgrade
|
Cash Interest Paid | 15.21 | 15.67 | 9.29 | 1.84 | 1.5 | Upgrade
|
Cash Income Tax Paid | 5.51 | 4.47 | 0 | -0.15 | -1.1 | Upgrade
|
Levered Free Cash Flow | -200.32 | -332.95 | -156.42 | -281.9 | -171.19 | Upgrade
|
Unlevered Free Cash Flow | -159.38 | -305.41 | -137.24 | -279.45 | -169.99 | Upgrade
|
Change in Net Working Capital | 96.95 | 103.83 | -146.25 | 55.07 | 4.42 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.